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Preclinical and clinical studies have demonstrated that zinc possesses antidepressant properties and that it may augment the 
therapy with conventional, that is, monoamine-based, antidepressants. In this review we aim to discuss the role of zinc in the 
pathophysiology and treatment of depression with regard to the monoamine hypothesis of the disease. Particular attention will 
be paid to the recently described zinc-sensing GPR39 receptor as well as aspects of zinc deficiency. Furthermore, an attempt will 
be made to give a possible explanation of the mechanisms by which zinc interacts with the monoamine system in the context of 
depression and neural plasticity.
1. Introduction
The original monoamine hypothesis of depression was
based on serendipitous discoveries. Clinical observations on
iproniazid, a tuberculostatic, and imipramine, which was
designed as a neuroleptic, showed that these medications
reduce depressive symptoms [1]. Extensive research on their
mechanism of action further revealed that iproniazid inhibits
monoamine oxidase (MAO), an enzyme responsible for
the oxidative deamination of monoamines, such as nore-
pinephrine (NE) and serotonin (5-hydroxytryptamine, 5-
HT), while imipramine, which became the first tricyclic
antidepressant (TCA), inhibits the serotonin transporter
(SERT) and the norepinephrine transporter (NET), which
account for clearance of the neurotransmitters from the
synaptic cleft [1]. These and other observations have con-
tributed to themonoamine hypothesis, which postulated that
depression is associated with decreased levels of NE and/or 5-
HT in the brain [2, 3]. Although the monoamine hypothesis
is now regarded as too simplistic to explain the complexity
of the pathophysiology of depression, it has led to the
development of antidepressants such as selective serotonin
reuptake inhibitors (SSRIs) or serotonin-norepinephrine
reuptake inhibitors (SNRIs), which are now widely used. It
should be noted that almost all currently used antidepressant
drugs target themonoamine system.However, the Sequenced
Treatment Alternatives to Relieve Depression (STAR∗D)
study, the largest and longest study conducted with the aim
of determining antidepressants effectiveness, demonstrated
that only one-third of the participants given an SSRI as a
first-line treatment reached remission, and that about 10–
15% more responded [4]. These data emphasize the need
for novel pharmacological treatments and/or augmentation
strategies for depression. It has been shown in preclinical and
Hindawi
Neural Plasticity
Volume 2017, Article ID 3682752, 18 pages
https://doi.org/10.1155/2017/3682752
2 Neural Plasticity
clinical studies that zinc possesses antidepressant properties
[5] and is able to enhance the effects of antidepressant drugs
belonging to the group of SSRIs or TCAs [6, 7]. This review
aims to discuss the role of zinc in the pathophysiology and
treatment of the disease with regard to the monoamine
hypothesis. Particular attention will be paid to the recently
described zinc-sensing GPR39 receptor [8] and aspects of
zinc deficiency. Furthermore, an attempt will be made to
give a possible explanation of the mechanisms by which
zinc interacts with the monoamine system in the context of
depression and neural plasticity.
2. Zinc
Recent years have brought a new evidence supporting the
involvement of zinc in depression in terms of both pharmaco-
logical and clinical/epidemiological data. Preclinical tests and
models of depression showed antidepressant-like activity of
zinc [9–15]. Clinical data pointed towards potential benefits
of zinc administration in depressed patients [16, 17]. Zinc
supplementation was shown to be effective as an adjunct
therapy [6, 7, 18] or as a stand-alone intervention [19, 20]
for depression. Moreover, the intake of zinc was suggested to
be among the dietary factors that may be associated with a
risk for depression. Studies performed in rodents indicated
a causative role of dietary zinc restriction in the induction
of depressive-like symptoms [21–24] or anhedonia [25–27].
Some large, cross-sectional, population-based epidemiolog-
ical studies have suggested that a low dietary zinc intake
is associated with depression in women [28, 29], but not
in men [28]. Although the first prospective study aimed to
examine the association of zinc intake and depression risk
demonstrated a modest, but significant, inverse correlation
between the intake of this element and depression in a
cross-sectional setting, the 20-year prospective follow-up
observations have indicated that a lowdietary zinc intakemay
not precede depression in initially depression-free men [30].
However, because the study sample comprised exclusively
men who have received a hospital discharge diagnosis of
unipolar depression, the results cannot be generalized to
women or patients not warranting hospitalization [30]. In
contrast, in a prospective study of both men and women, a
low dietary zinc intake emerged as a risk factor for depression
[31]. Also mice lacking the GPR39 receptor, a G protein-
coupled receptor, which is activated by zinc [8, 32], display
depressive-like behavior [33]. Recently, TCG-1008, an agonist
of GPR39, was found to exhibit antidepressant-like activity
[34]. These observations further support the involvement of
zinc in the treatment of depression.
In the human body zinc is the second most prevalent
trace element. It is necessary for proper brain development
and functioning. Even subclinical zinc deficiency impairs
human brain function [35]. In the brain the ion is present
in presynaptic vesicles of a subset of glutamatergic neurons
[36]. Somas of the zinc containing neurons are located in the
cerebral cortex and in the amygdala, whereas their axonal
projections reach cerebral cortex and amygdala, striatum as
well as structures of the limbic system [37]. Zinc is packed
into the synaptic vesicles by means of a zinc transporter 3
(ZnT-3) [38], which is localized on the membranes of the
vesicles [39]. After action potential it is released from the
presynaptic vesicles into the synaptic cleft. To date, there is
no consensus on the concentration to which the ion rises
in the synaptic cleft or its time-course. It is estimated to
range from sub-𝜇M to over 100 𝜇M [40]. Zinc released from
the presynaptic vesicles modulates a variety of receptors or
transporters on the postsynaptic side, including those for
monoamines [41, 42].
3. Serotonin (5-HT)
In 1967 Coppen emphasized the role of 5-HT in the patho-
physiology of depression [2]. Approximately 90% of 5-HT is
synthesized by enterochromaffin cells in the gastrointestinal
tract, while most of the remaining 5-HT is produced by
the neurons of the raphe nuclei in the brain. The axonal
projections of the raphe nuclei innervate almost the entire
central nervous system (CNS), and thus play an impor-
tant role in the regulation of mood, memory, cognition,
sleep, appetite, and so forth. 5-HT is synthesized from the
precursor amino acid L-tryptophan [43, 44]. After trypto-
phan is transported into the 5-HT neuron, it is converted
by tryptophan hydroxylase, the rate-limiting enzyme in 5-
HT production. Aromatic amino acid decarboxylase then
converts 5-hydroxytryptophan into 5-HT, which is taken up
into the synaptic vesicles by the vesicular monoamine trans-
porter (VMAT2) [45]. Tryptophan can be also catabolized by
indoleamine 2,3-dioxygenase (IDO) into kynurenine, which
is further broken down into kynurenic acid and quinolinic
acid [46]. Activation of the IDO pathway causes lowered
plasma tryptophan availability to the brain and, subsequently,
lower production of 5-HT [47]. MAO, which is localized
in the mitochondrial outer membrane, degrades 5-HT [46].
SERT, which belongs to the neurotransmitter/sodium sym-
porter family besides NET and dopamine transporter (DAT),
is a high-affinity transporter for 5-HT and plays a crucial
role in maintaining its extracellular levels [48]. Drugs that
selectively inhibit SERT, namely, SSRIs, have revolutionized
clinical psychopharmacology and nowadays are among the
first-line medications used for depression [4]. Although the
newest drugs, such as the multimodal agent vortioxetine,
combine action occurring at different 5-HT receptor sub-
types, SERT inhibition remains an important element of their
action [49]. The current view on the mechanism of action
of SSRIs states that, following acute treatment, the 5-HT
level rises in the somatodendritic area located in the raphe
nuclei and stimulates the 5-HT1A autoreceptors. Following
chronic use, the 5-HT1A receptors become downregulated
and desensitized and thus no longer inhibit 5-HT release.
This leads to increased 5-HT release from the axon terminals
[50]. As well as targeting SERT, vortioxetine targets 5-HT G-
protein-coupled (5-HT1A and 5-HT1B partial agonism and 5-
HT7 antagonism) and 5-HT ionotropic (5-HT3 antagonism)
receptors [49]. Other medications, such as trazodone, as well
as inhibiting SERT, possess 5-HT2A and 5-HT2C antagonistic
properties [51].
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3.1. The Interaction of Zinc with the Serotonergic System.
Several preclinical studies have shown the interaction of
zinc with the components of the serotonergic system with
regard to its antidepressant-like action. Pretreatment with
p-chlorophenylalanine (pCPA), an inhibitor of 5-HT syn-
thesis, abolished the antidepressant-like effect of zinc in
the forced swim test (FST), which is a common preclinical
paradigm used to assess antidepressant properties [52]. The
antidepressant-like effect of zinc in the FST was also blocked
by the 5-HT1A receptor antagonist WAY-100635 [52]. A study
by Cichy et al. [53] showed adaptive changes in serotonergic
receptors following chronic zinc hydroaspartate administra-
tion. Treatment with zinc for 2 weeks increased the density of
the hippocampal and cortical 5-HT1A and 5-HT2A receptors
in rats. Similarly, adaptive changes of 5-HT1A and 5-HT2A
receptors were found following chronic administration of
imipramine [54].
Effect on serotonergic receptors is one of the explana-
tions of the antidepressant-like properties of zinc, which
are observed in both preclinical and clinical studies. Satała
et al. [42] extensively explored the pharmacological profile
of zinc at the 5-HT1A receptors using the agonist of 5-
HT1A, [3H]-8-OH-DPAT. In this study, the effects of zinc
on [3H]-8-OH-DPAT binding to 5-HT1A stably expressed
in HEK293 cells were investigated by means of the in
vitro radioligand binding method. A biphasic effect, which
involved allosteric potentiation of agonist binding at sub-𝜇M
zinc concentrations and inhibition at sub-mM zinc concen-
trations, was observed [42]. Given that it is estimated that
after depolarization the concentration of zinc in the synaptic
cleft ranges from sub-𝜇Mto 100 𝜇M[40], the effects observed
with lower doses should be physiologically more relevant.
Additionally, in vivo studies, aimed at differentiating between
action at pre- and postsynaptic 5-HT1A, demonstrated that
zinc did not induce lower lip retraction or elements of
behavioral syndrome (flat body posture, forepaw treading),
but pretreatment with zinc blocked these effects induced
by the agonist [3H]-8-OH-DPAT, which suggest that zinc
may act as an antagonist of this receptor at the postsynaptic
site. However, zinc decreased body temperature similarly
to [3H]-8-OH-DPAT. On the other hand, the experiments
using 5-HT1A autoreceptor knockout mice showed that lack
of this receptor completely blocked the hypothermia induced
by zinc, while in wild-type littermate mice a consistent
decrease in body temperature was observed, which may
indicate agonist-like profile at the presynaptic 5-HT1A. In
the FST ineffective doses of zinc potentiated the effects of
ineffective doses of [3H]-8-OH-DPAT. In the FST conducted
with 5-HT1A autoreceptor knockout mice zinc induced a
slight decrease in the immobility time while in wild-type
littermates a significant decrease in the immobility time was
observed, which suggest that presynaptic 5-HT1A receptors
are necessary for the antidepressant-like effect of zinc [42]. To
sumup, this comprehensive study shows that zinc (depending
on its concentration) may act as positive allosteric modulator
of agonist binding to 5-HT1A receptors or inhibitor.Moreover,
both agonist and antagonist-like effectswere found and itmay
target both pre- and postsynaptic 5-HT1A.
A 10-day administration of pCPA, an inhibitor of 5-HT
synthesis, caused downregulation of GPR39 protein in the
hippocampus of mice [55], which suggests a link between
GPR39 and 5-HT signaling. There was also a decrease in the
level of 5-HT precursor, tryptophan, in the hippocampus of
GPR39 knockoutmice [55].Moreover, there is some evidence
indicating a link between GPR39 and 5-HT1A receptors func-
tion. GPR39 was found to form heterodimers with 5-HT1A
as well as heterotrimers with 5-HT1A and galanin receptor
1 (GalR1) upon coexpression of the two or three of them in
mammalian cells [56]. Galanin is a neuropeptide which is
widely distributed in the brain andwhose effects aremediated
via three G protein-coupled receptors: GalR1, GalR2, and
GalR3 [57]. 5-HT1A and GalR1, which share the same signal
transduction pathway (i.e., activate G𝛼i protein which leads
to inhibition of adenylyl cyclase), have been described to het-
erodimerize and functional characteristic of the heterodimers
revealed absence of addictive effects what can be explained
by the existence of allosteric antagonistic communication
to avoid excessive inhibition of adenylyl cyclase [58]. Fur-
thermore, zinc was found to disrupt the heterodimeriza-
tion process of 5-HT1A and GalR1 [59]. Activities of the
monohomomeric receptors: 5-HT1A, GalR1, and GPR39, and
the heteroreceptor complexes: 5-HT1A-GPR39 and 5-HT1A-
GPR39-GalR1, were measured by their ability to activate
response elements: the serum response element (SRE) and
nuclear factor kappa beta response element (NF𝜅𝛽-RE) [56].
Because GPR39 signals via Gq, G𝛼12/13, and G𝛼s proteins [32],
which leads to activation of both response elements, whereas
5-HT1A signals via G𝛼i protein [60] and activates SRE only
in the presence of agonist, 8-OH-DPAT, SRE, and NF𝜅𝛽-
RE were chosen to analyze potential differences in signaling
between monohomomers and heteromers [56]. 5-HT1A-
GPR39 heteromer exposure to 8-OH-DPATand zinc chloride
resulted in higher response compared to those yielded by
each one of the compounds indicating additive signaling
upon coactivation of these receptors. The complex including
also GalR1 (5-HT1A-GPR39-GalR1 heteromer) displayed no
response in the presence of 8-OH-DPAT or zinc chloride, but
enhancement of response was observed in the presence of
galanin, while stimulation with all agonists together evoked
the same response as galanin, suggesting that the presence of
GalR1 blocks 5-HT1A and GPR39 signaling.
In addition to targeting 5-HT1A receptors, zinc was
found to target other subtypes of 5-HT receptors. Elec-
trophysiological studies of HEK293 cells expressing 5-HT3
receptors showed that low concentrations of zinc (0.3–10 𝜇M)
enhanced and high concentrations of zinc (30–200𝜇M)
depressed the 5-HT-induced response [61]. 5-HT reuptake by
SERT is not affected by zinc [62].
3.2. Interactions between Zinc and Antidepressants Target-
ing the Serotonergic System. Preclinical and clinical studies
showed that zinc interacts with the serotonergic system and
therefore enhances antidepressant-like effects. Joint admin-
istration of zinc with SSRIs such as fluoxetine or citalopram
(all in subeffective doses) produced an antidepressant-like
effect in the FST [52]. Moreover, an increase in the swimming
parameter, but not in the climbing parameter, in the FST was
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observed following zinc administration [52]. It is suggested
that in the FST the swimming parameter is connected
with serotonergic neurotransmission, and the climbing is
linked to noradrenergic neurotransmission (based on the
observation that SSRIs increase the swimming time whereas
selective norepinephrine reuptake inhibitors (NRIs) increase
the climbing time [63]). Thus, these results suggest that the
serotonergic system is involved in the antidepressant-like
activity of zinc. Combined administration of zinc chloride
with SSRIs such as fluoxetine or paroxetine significantly
reduced immobility scores in the tail suspension test (TST),
another preclinical paradigm used to assess antidepressant
activity, without affecting locomotion in the open field test
[13]. Moreover, joint administration of zinc and imipramine
(both in ineffective doses) caused an antidepressant-like
effect in the chronic unpredictable stress (CUS) protocol,
which is a commonly used preclinical model of depression
[14]. Imipramine was also found to be active in the FST
following the administration of ineffective doses together
with ineffective doses of zinc sulfate [11, 12]. Wróbel et al.
[64] demonstrated antidepressant-like properties of zinc in
a dexamethasone-induced model of depression in mice. In
this study, the joint administration of zinc and imipramine
(both in ineffective doses) reversed dexamethasone-induced
depressive-like behavior, as measured by the FST.
The interaction between zinc and antidepressants tar-
geting the serotonergic system has been observed not only
following zinc supplementation, but also under zinc-deficient
conditions. Chronic administration of the zinc-deficient diet
was found to alter the responsiveness to antidepressant
drugs [65]. Animals subjected to a zinc-deficient diet and
treated with an acute injection of escitalopram or imipramine
displayed increased immobility time in the FST, compared to
animals treated with a zinc-adequate diet and the respective
antidepressant agent [65]. Additionally, increased immobility
time was observed in mice that received a zinc-deficient diet
and chronic treatment with escitalopram, compared to mice
that received a zinc-adequate diet and the drug, whereas
chronic imipramine treatment did not result in such differ-
ences between the zinc-deficient and zinc-adequate rats [65].
Chronic dietary deprivation of zinc produces a depressive-
and anxiety-like phenotype [22–24, 66, 67]. Chronic admin-
istration of fluoxetine to the zinc-deficient rats resulted in
the normalization of depressive-like behavior induced by
the diet, as measured by decreased immobility time in the
FST [66]. On the contrary, Tassabehji et al. [25] did not
observe a significant reduction in the immobility time in the
zinc-deficient rats treated with fluoxetine, compared to zinc-
deficient rats that did not receive the antidepressant. How-
ever, Tassabehji et al. [25] also did not observe depressive-like
behavior (increased immobility time) in the zinc-deficient
rats compared to control rats. This finding may have resulted
from different study design. In the study of Doboszewska et
al. [66] the rats received the zinc-deficient diet for 4 weeks
(i.e., for a period of time after which behavioral (increased
immobility time in the FST, anhedonia) and neurobio-
logical changes associated with depression are established
[27]) and for subsequent 2 weeks they received fluoxetine
(10mg/kg/day intraperitoneally (i.p.)) in addition to the
diet, whereas in the study of Tassabehji et al. [25] the rats
received the zinc-deficient diet and fluoxetine (10mg/kg/day
via drinking water) for 3 weeks.Therefore, a shorter duration
of the zinc-deficient diet in the study of Tassabehji et al.
[25] (3 weeks) may have been an insufficient amount of
time in which to observe a depressive-like behavior. Yet
other authors demonstrated depressive-like behavior in the
FST following a shorter duration of the zinc-deficient diet,
namely, 2 weeks [21, 68]. It should be noted that Tassabehji
et al. [25] observed anhedonia, which is one of the core
symptoms of depression, in the zinc-deficient rats. Whereas
the two studies in which increased immobility time in the
FST following 2 weeks of the diet utilized the zinc-deficient
diet containing 0.37mg zinc/kg and the zinc-adequate diet
containing 52.8mg zinc/kg [21, 68], similarly, we utilized the
following diets: zinc-deficient 3mg zinc/kg; zinc-adequate
50mg zinc/kg [66], the study which did not demonstrate a
depressive-like behavior after 3 weeks of the diet utilized:
zinc-deficient diet 1mg/kg; zinc-adequate diet 30mg/kg [25].
Hence, when interpreting data on the effectiveness of antide-
pressants in the zinc-deficient animals it is important to take
into account the duration of the diet, the amount of the
ion, and the schedule of treatment. Positive behavioral effects
(reversal of depressive-like behavior) in zinc-deficient mice
were observed following chronic treatment with desipramine
(a TCA with a less potent inhibitory effect on 5-HT than on
NA reuptake) in the FST and the TST [22].
Administration of antidepressants that influence the
serotonergic system under zinc-deficient conditions also
normalized changes that were observed in the brain.
Fluoxetine prevented the higher levels of the hippocampal
N-methyl-D-aspartate receptor (NMDAR) subunits (GluN1,
GluN2A, GluN2B) and the reduced levels of phosphorylated
on Serine-845 GluA1 subunit of alpha-amino-3-hydroxy-
5-methyl-4-isoxazole-propionic acid receptor (AMPAR)
(pS485-GluA1), phosphorylated cyclic AMP response
element binding protein (p-CREB) and brain-derived
neurotrophic factor (BDNF) that were evoked by zinc
deficiency [66]. Chronic desipramine treatment normalized
the exaggerated immediate-early gene expression in the
amygdala that was induced by zinc deficiency [22].
There is also a link between GPR39 receptor and
antidepressants acting on the 5-HT system. Chronic (a 2-
week) treatment with escitalopram but not with imipramine
induced upregulation of GPR39 receptor at the protein
level in the frontal cortex of mice [69]. Moreover, acute
administration of imipramine or escitalopram to mice fed
with the zinc-deficient diet caused downregulation of GPR39
protein, while chronic administration of these agents (which
is required in order to relieve depressive symptoms) induced
upregulation of this protein in the frontal cortex of mice
[70]. Furthermore, imipramine and escitalopram reduced
immobility time in the FST in wild-type mice, but they
were inactive in this paradigm in GPR39 knockout mice,
which suggest that GPR39 receptor is necessary for the
antidepressant effect of drugs targeting the 5-HT system [71].
Besides preclinical studies, clinical studies have also
demonstrated the interaction between zinc and antidepres-
sants targeting the serotonergic system. The first clinical
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report indicating the beneficial effects of zinc in human
depression showed that it is effective as an augmentation
strategy in conjunctionwithTCAs (clomipramine, amitripty-
line) or SSRIs (citalopram, fluoxetine) [6]. This preliminary
observation was further confirmed in trials using a big-
ger sample size. The study of Ranjbar et al. showed that
zinc supplementation of therapy involving administration of
SSRIs, citalopram or fluoxetine, reduced major depressive
disorder symptoms more effectively than administration of
the respective drug plus placebo [7]. This effect was not
associated with changes in plasma levels of IL-6, TNF-
𝛼 or BDNF [72]. Importantly, zinc supplementation of
therapy involving administration of imipramine was found
to be more effective than administration of imipramine
plus placebo in treatment-resistant patients [18]. Although
a recent systematic review and meta-analysis of adjunctive
nutraceuticals for depression found mixed results for zinc
[17], zinc supplementation shows promise as a strategy for
improving an inadequate response to antidepressants.
3.3. Effects on Zinc Levels of Antidepressants Targeting the
Serotonergic System. In preclinical studies, chronic treatment
with citalopram (but not with imipramine) significantly
increased the serum zinc level. Chronic treatment with both
drugs slightly increased the zinc level in the hippocampus
and slightly decreased it in the cortex, the cerebellum and the
basal forebrain [73]. Moreover, escitalopram and imipramine
normalized serum zinc levels previously reduced by a 6-
week zinc-deficient diet [65]. Also, chronic treatment with
fluoxetine normalized a decrease in the serum zinc level
induced by dietary zinc deficiency [66].
A clinical study by Maes et al. [74] examining the
serum zinc level in treatment-resistant depression showed
a decreased serum zinc level in treatment-resistant patients
compared with healthy controls and patients who were not
resistant to treatment.The study also showed that subsequent
treatment with antidepressants for 5 weeks (with trazodone
alone or in combination with fluoxetine and pindolol) did
not induce significant changes in the level of serum zinc.
Therefore, the serum zinc level was proposed as a marker
for treatment resistance. Moreover, a study of the use of
zinc supplementation in imipramine therapy showed signif-
icantly lower serum zinc level in depressed patients than
in healthy volunteers. All groups demonstrated a gradual
increase in zinc concentrations over the period of treatment
with imipramine with or without zinc supplementation. It
is of note that treatment-resistant patients demonstrated
lower concentrations of zinc than patients who were not
resistant to treatment. Importantly, following 12 weeks of
treatment with imipramine, a significant negative correlation
was demonstrated between theMontgomery-ÅsbergDepres-
sion Rating Scale and the serum zinc level, together with a
concomitant increase in serum zinc in patients in remission,
which suggests that the serum zinc level is a state marker
for depression (with the exception of treatment-resistant
patients for whom it may be a trait marker) [75]. More
studies are needed in a clinical setting to elucidate the effects
of antidepressants with different mechanisms of action on
serum zinc.
4. Norepinephrine (NE)
NE, also called noradrenaline (NA), is one of the prin-
cipal catecholaminergic neurotransmitters that have been
implicated in the monoamine hypothesis of depression and
antidepressant action [3].
NE is synthesized by both the CNS and the sympathetic
nervous system. In the brain, NE is produced in nuclei, of
which the most important is the locus coeruleus (LC), the
most extensively projecting nucleus in the brain [76, 77]. The
NE projections from the LC reach brain regions such as the
cortex, the hippocampus and the amygdala, which govern
memory, cognition andmood [78]. Exposure to stress, which
is considered to be a precipitant of depression [79], activates
the LC through efferents from the corticotropin-releasing
factor (CRF) system [80]. Therefore, LC projections and
inputs have received great attention with regard to depressive
disorders.
NE is synthesized from the precursor amino acid tyrosine
by a series of enzymatic steps. Tyrosine is transported to
the CNS from the blood by means of an active transport
pump. First, tyrosine is converted into DOPA by tyrosine
hydroxylase, the rate-limiting enzyme in NE synthesis.Then,
DOPA is converted into dopamine (DA) by DOPA decar-
boxylase. The third enzymatic step is the conversion of DA
into NE by dopamine 𝛽-hydroxylase. While the first two
steps occur predominantly in the cytoplasm, the last one
takes place mainly in the synaptic vesicles. NE is degraded to
inactive metabolites by either MAO [81], which is localized
in the mitochondrial outer membrane [82], or catechol-O-
methyltransferase (COMT) [81], which is located intracel-
lularly [83]. The other mechanism terminating synaptic NE
action isNET,which belongs to the neurotransmitter/sodium
symporter family and which is localized on the presynaptic
noradrenergic nerve terminals [84, 85]. Following reuptake
into the presynaptic neuron by NET, NE can be either stored
again in the synaptic vesicles by the VMAT2 [86] or degraded
by enzymes. NE exerts its action via the family of G protein-
coupled receptors (𝛼 and 𝛽 subtypes). Of particular interest
in terms of antidepressant pharmacology are 𝛼2 adrenergic
receptors, which can act as presynaptic autoreceptors, and
thereby regulate NE release [87, 88]. Many antidepressants
target NET (e.g., SNRIs such as venlafaxine, duloxetine, and
milnacipran; norepinephrine-dopamine reuptake inhibitors
(NDRIs) such as bupropion; selective norepinephrine reup-
take inhibitors (NRIs) such as reboxetine; and TCAs such as
imipramine and amitriptyline) and/or adrenergic receptors
(e.g., drugs with prominent 𝛼2-blocking properties, such
as mirtazapine and mianserin). Moreover, chronic admin-
istration of antidepressants induces adaptive changes in the
adrenergic receptors (i.e., 𝛽-downregulation [89, 90], 𝛼1-
upregulation [91, 92], or 𝛼2-downregulation [90]).
4.1. Interactions between Zinc and the Noradrenergic System.
Despite a high sequence identity between DAT, which pos-
sesses an endogenous, high-affinity zinc-binding site, and
NET, the latter does not possess a zinc-binding site [41]. NET
contains two of the three zinc coordinating residues found
in DAT, but monoamine reuptake by NET is not affected by
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zinc. However, if the third DAT zinc coordinating residue
(H193) is introduced into NET (position 189), NET becomes
susceptible to inhibition by zinc [93]. It has been reported that
the expression of NET was decreased in the locus coeruleus
by the cooccurrence of social isolation and zinc deficiency
comparedwith zinc deficiency alone, and that this changewas
accompanied by an increase in the blood concentration of 3-
methoxy-4-hydroxyphenylglycol (MHPG), anNEmetabolite
[94]. It was long assumed that the peripheral measurement
of MHPG reflects similar activity of the CNS NE system;
however, further studies have shown that the brain contains
about 20% of the peripheral levels of this metabolite [81].
Apart from NET, zinc targets other NE system compo-
nents, including the 𝛼1 and 𝛽2 receptors, which are expressed
in the CNS and which are implicated in the pathophysiol-
ogy of depression and antidepressant action [95]. The ion
interacts with the 𝛼1A-adrenoceptor with affinities in the low
𝜇M range and acts as a negative allosteric modulator for
this receptor [96]. Moreover, it acts as a positive allosteric
modulator for NE, which suggests that it may bind to
two distinct binding sites of the 𝛼1A [96]. Zinc is also a
positive allosteric modulator of agonist binding for the 𝛽2-
adrenoreceptor [97, 98].
Zinc administrationmay affect levels of centralNE and/or
levels of its metabolites. A 3-day i.p. administration of 5mg
zinc acetate/kg body weight resulted in a significant increase
in NE levels in the whole brains of rats, whereas DA levels
slightly decreased [99]. Wallwork et al. [100] observed that
the NE level increased in the brains of rats fed a zinc-deficient
diet for 9-10 days compared with pair-fed or ad libitum-fed
control rats, which received the same diet as the zinc-deficient
group but were given zinc acetate via their drinking water.
When measured by in vivo microdialysis, NE concentration
was found to have decreased in the paraventricular nucleus
(PVN) of the hypothalamus of rats fed the zinc-deficient
diet for 2 weeks compared with rats fed the zinc-adequate
diet [101]. Moreover, decreased concentrations of NE and its
metabolite 3,4-dihydroxyphenylglycol (DHPG) were found
in the PVN of rats subjected to a 2-week zinc-deficient diet,
and this was associated with increased NE activity measured
as a higher ratio of DHPG to NE [102]. These data indicate
that dietary zinc deficiency may also affect central NE levels.
Furthermore, prenatal exposure to zinc oxide nanoparticles
was found to increase the level of normetanephrine, another
NE metabolite, in the hippocampus of mouse offspring, as
well as to decrease the MHPG level in the hypothalamus and
cerebellum; however, it did not affect the NE level in any of
the brain regions examined [103].
4.2. Interactions between Zinc and Antidepressants Targeting
the Noradrenergic System. Zinc was found to be active in a
number of preclinical tests (e.g., FST, TST) and models of
depression [9–13, 15]. Low, ineffective doses of zinc adminis-
tered together with low, ineffective doses of imipramine were
active in the FST [104] and the TST [13]. However, the com-
bined treatment of subeffective doses of zinc and reboxetine
did not result in a significantly reduced immobility time in the
FST [52]. Moreover, an increase in the swimming parameter
but not in the climbing parameter in the FST was observed
following zinc administration [52]. It is suggested that in the
FST the swimming parameter is connected with serotonergic
neurotransmission, and the climbing parameter is linked to
noradrenergic neurotransmission [63]. Therefore, the above-
mentioned results suggest that the noradrenergic system
is not involved in the antidepressant-like activity of zinc.
However, this may be a phenomenon observed only in the
FST, as combined treatment, involving the administration of
subeffective doses of zinc chloride together with subeffective
doses of desipramine, a TCA with better selectivity for NE
reuptake, induced a significant reduction in immobility time
in the TST [13].
Zinc deficiency induces depression-like behavior [21, 22,
24, 25, 27]. Animals subjected to a zinc-deficient diet and
treated with an acute injection of imipramine or reboxetine
displayed increased immobility time in the FST compared
with animals treated with a zinc-adequate diet and the
respective antidepressant [65]. Also, increased immobility
time was observed in mice fed a zinc-deficient diet after
chronic reboxetine administration, compared withmice fed a
zinc-adequate diet and treated with the antidepressant drug,
whereas chronic imipramine treatment in mice subjected to
either a zinc-deficient or a zinc-adequate diet resulted in
no significant differences in immobility time between the
groups [65]. These results indicate that zinc deficiency alters
responsiveness to antidepressants targeting the NE system.
The zinc-sensing GPR39 receptor is involved in the
pathophysiology of depression and antidepressant action
[32]. Chronic treatment with reboxetine but not with
imipramine induced upregulation of the GPR39 protein in
the frontal cortex of mice [69]. GPR-39 knockout mice
display depressive-like behavior [33]. While imipramine and
reboxetine reduced immobility time in the FST in wild-type
(WT)mice, they were inactive in this test in GPR39 knockout
mice, suggesting that the GPR39 receptor is required for the
antidepressant effect of antidepressants targeting the nora-
drenergic system [71].Moreover, administration of𝛼-methyl-
p-tyrosine, an inhibitor of tyrosine hydroxylase, the rate-
limiting enzyme in NE synthesis, which causes inhibition of
NE and DA synthesis, induced upregulation of the GPR39
protein level in the frontal cortex after a 3-day administration
and downregulation of this receptor in the hippocampus after
a 10-day administration [55], indicating a possible role of the
GPR39 receptor in NE transmission.
The first communication suggesting a beneficial effect
of zinc supplementation in clinical depression showed
that patients receiving TCAs (clomipramine, amitriptyline)
together with zinc displayed significantly reduced depression
scores compared with patients receiving TCAs and placebo
[6]. Furthermore, a randomized, double-blind, placebo-
controlled study showed that zinc supplementation augments
the efficacy of imipramine in treatment-resistant patients
[18]. Whereas zinc supplementation of therapy with SSRIs
was found to be beneficial in depressed patients [7], so far no
study has examined the effects of the joint administration of
zinc and an antidepressant selectively blocking NE reuptake.
4.3. Effects on Zinc Levels of Antidepressants Targeting the
Noradrenergic System. Repeated treatment with imipramine
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slightly increases the zinc level in the hippocampus and
slightly decreases it in the cortex, the cerebellum, and the
basal forebrain, but it does not affect the serum zinc level
[73]. No significant differences were observed in the serum
zinc level between mice that received a zinc-deficient diet
and chronic imipramine or reboxetine treatment and mice
that received a zinc-adequate diet and the respective drug
treatment, while the level of the stress hormone, corticos-
terone, was increased in the serum of the zinc-deficient mice
[65]. A clinical study inwhich zinc supplemented imipramine
therapy found a significantly lower serum zinc level in
depressed patients than in healthy volunteers. All groups
demonstrated a gradual increase in zinc concentrations
over the period of imipramine treatment with or without
zinc supplementation. It is of note that treatment-resistant
patients demonstrated lower concentrations of zinc than
patients who were not resistant to treatment. Importantly,
over the course of 12 weeks of imipramine treatment, a
significant negative correlation was demonstrated between
the Montgomery-Åsberg Depression Rating Scale and the
serum zinc level, together with a concomitant increase in
serum zinc in patients in remission [75]. So far no study has
examined the effects of antidepressants that selectively block
NE reuptake on serum zinc level in a clinical setting.
5. Dopamine (DA)
Dopamine (DA), another catecholaminergic neurotransmit-
ter, has initially received less attention in relation to the
original monoamine hypothesis of depression; however, in
the 1970s its role was postulated [105].
In the brain, most DA-synthesizing neurons are located
in the brainstem nuclei: the substantia nigra and the ventral
tegmental area (VTA). VTA neurons project to the cortex via
the mesocortical pathway, and to the nucleus accumbens, the
hippocampus and the amygdala via the mesolimbic pathway.
Projections from the substantia nigra to the dorsal striatum
constitute the nigrostriatal pathway. The other pathway is
the tuberoinfundibular pathway, which regulates prolactin
secretion [106]. DA pathways are involved in various CNS
functions, such as memory, learning, attention, movement,
reward, and affect [106].
DA is synthesized from the amino acid tyrosine and is
a precursor for NE. Tyrosine hydroxylase converts tyrosine
into DOPA, whereas DOPA decarboxylase converts DOPA
into DA. After synthesis, which occurs in the cytoplasm,
DA is transported into the synaptic vesicles by VMAT2.
DA is cleared from the extracellular space by DAT, which,
like NET and SERT, belongs to the neurotransmitter/sodium
symporter family and is inactivated by COMT andMAO.The
prefrontal cortex possesses a fewDATs, andDA is terminated
in this region by NET [106, 107]. DA exerts its action via
G protein-coupled D1-like (D1, D5) and D2-like (D2, D3,
D4) receptors, which are widely expressed in the brain [107].
Pharmacological agents targetingDA system components are
largely used in the treatment of psychiatric and neurological
diseases (e.g., schizophrenia, bipolar disorder, depression,
Parkinson’s disease, attention deficit hyperactivity disorder).
Bupropion, which belongs to the NDRIs, is among the
antidepressants targeting DAT [108]. Unlike SSRIs, it has a
very low rate of sexual dysfunction being experienced as a
side effect [108]. Sertraline is among the SSRIs which inhibit
DAT [109]; however, it remains controversial whether this
action is clinically relevant. Nevertheless, adding bupropion
to SSRI therapy is effective as an augmentation strategy
[108], and adding bupropion to sertraline treatment is also
effective, probably because of the combination of the weak
DAT properties of both. It should be noted that drugs
inhibiting NET cause an increase in the DA level in the
prefrontal cortex. Additionally, chronic administration of
antidepressants induces adaptive changes to DA receptors
(D1-downregulation [110] and D2-upregulation [111]), and
DA receptors are involved in the antidepressant-like effect of
different compounds [95].
5.1. Zinc Interactions with the Dopaminergic System. The
binding of zinc to DAT is long established. Extracellular
zinc binds to DAT and restricts the transporter’s movement
through the conformational cycle, resulting in a decrease in
substrate uptake. Two major coordinating histidine residues
(H193 in the large second extracellular loop (ECL2) andH375
in the fourth extracellular loop (ECL4)) in the zinc-binding
site of DAT were identified [93]. Next, it was shown that the
zinc-binding site of DAT consists not only of H193 and H375
but also of E396 and D206 [112]. Extracellular zinc is a potent
inhibitor of DAT in cells expressing human DAT [93] and
in synaptosomes [113] with an IC50 in the low 𝜇M range.
Considering that after depolarization the concentration of
zinc in the synaptic cleft is estimated to be between sub-𝜇M
and 100 𝜇M [40], zinc action on DAT seems to be physi-
ologically relevant. Also, zinc modulates the dopaminergic
receptors. The ion was reported to allosterically inhibit the
binding of subtype-specific antagonists of the D1A and D2L
receptors [114]. The binding of the selective antagonists to
the respective receptors was reduced in the presence of 𝜇M
zinc concentrations [114]. Moreover, it was shown that zinc
inhibits the binding of the selective antagonist (spiperone
analogue: [3H]methylspiperone) to D2-like receptors. Zinc
inhibition of antagonist binding to the D4 receptor was found
to be noncompetitive, whereas in the case ofD2L andD3 it was
found to be a competitive allosterism [115]. Zincwas shown to
modulate antagonistic binding to the entireD2-like subfamily
with concentrations in the low 𝜇M range [115]. Furthermore,
it was found that zinc binding to H394 and H399 on the
dopamine D2 receptor contributes to the allosteric regulation
of antagonist binding [116].
An increased DA level in the hippocampus of mouse
offspring following prenatal exposure to zinc oxide nanopar-
ticles was observed [103]. This change was associated with
increased levels of DA metabolites: homovanillic acid in
the prefrontal cortex and in the hippocampus, as well as
3,4-dihydroxyphenylacetic acid (DOPAC) in the prefrontal
cortex [103]. Prenatal exposure to zinc oxide nanoparticles
also increased DA turnover in the prefrontal cortex, the
neostriatum, the nucleus accumbens and the amygdala [103].
There were no changes in DA, DOPAC, or DOPAC-to-DA
ratios in the PVNof rats subjected to administration of a zinc-
deficient diet [102].
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5.2. Interactions between Zinc and Antidepressants Targeting
the Dopaminergic System. The joint administration of low,
ineffective doses of bupropion and low, ineffective doses of
zinc produced a significant decrease in immobility time in
the TST, which suggests the involvement of dopaminergic
neurotransmission in the antidepressant-like activity of zinc
[13, 52]. Animals subjected to a zinc-deficient diet and treated
with an acute injection of bupropion showed increased
immobility time in the FST compared with animals treated
with a zinc-adequate diet and the drug [65]. In addition,
increased immobility time was observed in mice fed a
zinc-deficient diet after chronic bupropion administration,
compared with mice fed a zinc-adequate diet and given the
antidepressant [65]. These behavioral changes were asso-
ciated with increased serum corticosterone concentrations
[65]. In animals chronically administered with bupropion,
the serum zinc concentrations did not differ between those
that received zinc-deficient diets and those that received zinc-
adequate diets [65].
To date, no clinical study has examined the effects of the
joint administration of zinc and antidepressants targetingDA
reuptake or the effects of administration of antidepressants
with this mechanism of action on serum zinc levels.
6. Link to Neural Plasticity
In 1998, after the pioneeringwork ofAltman [117], followedby
the studies of Kaplan and Hinds [118], contrary to the earlier
dogma which stated that the adult nervous system does not
produce new neurons, Eriksson et al. [119] demonstrated
the occurrence of neurogenesis in the dentate gyrus of the
hippocampus of adult humans. The discovery had a great
impact on the way of thinking about the human brain
and diseases. Preclinical and clinical studies have suggested
that the pathophysiology of depression is associated with
the inability of neuronal systems to exhibit appropriate
plasticity [120]. It was shown that psychosocial stress causes
atrophy of CA3 pyramidal cells in the hippocampus [121] and
decreases neurogenesis in the dentate gyrus of adult animals
[122]. It was postulated that these damaging effects of stress
could contribute to the reduced volume of the hippocampus
observed in depressed patients [123].The initial report on the
effect of antidepressants on hippocampal neurogenesis in the
adult rats has contributed to the neural plasticity theory of
depression and antidepressant action [124]. The antidepres-
sants tested in the first series of studies aimed to examine their
effects on the production of neurons in the adult rat brain
included a MAO inhibitor: tranylcypromine, an SSRI: fluox-
etine, and an NRI: reboxetine, as well as electroconvulsive
seizures. It was shown that chronic antidepressant treatment
(14–21 days in case of the above-mentioned drugs, 10 days in
case of electroconvulsive seizures) significantly increased the
number of cells positive for bromodeoxyuridine (BrdU), the
thymidine analogue that labels DNA during the S-phase, in
the dentate gyrus of the hippocampus [124], one of a few brain
regions where production of neurons occurs throughout
the lifetime [119]. In contrast, administration of fluoxetine
for 1 or 5 days did not significantly affect the number of
BrdU-positive cells [124], consistent with the finding that
antidepressants require weeks to produce therapeutic effect.
Angiogenesis is a process coupled to neurogenesis. It was
shown that SSRIs increased human hippocampal progenitor
cells and angiogenesis selectively in the anterior and central
dentate gyrus suggesting angiogenesis as a therapeutic strat-
egy [125]. Also newer compounds, like a multimodal agent
vortioxetine, after chronic treatment were shown to increase
dendritic length and the number of dendrite intersections
as well as to increase cell proliferation, cell survival and
stimulate maturation of immature granule cells in the sub-
granular zone of the dentate gyrus [126]. Moreover, vortiox-
etine [127] but also other generations of antidepressants like
SSRIs (escitalopram) [128] or SNRIs (milnacipran) [129] were
found to prevent the effects of stress on hippocampal long
term potentiation (LTP), one of the phenomena underlying
synaptic plasticity [130]. In the next paragraphwewill discuss
the role of zinc in the processes related to neural plasticity
and then possible interactions between zinc andmonoamine-
based antidepressants in the context of neural plasticity.
6.1. Zinc and Neural Plasticity. Adult male rats fed with a
zinc-deficient (1mg zinc/kg) diet for 3 weeks had ca. 50%
fewer stem cells positive for Ki67, a marker for proliferation
(which is expressed in cells that are in all active phases of the
cell cycle but not expressed in G0 phase), in the subgranular
zone and granular cell layer of the dentate gyrus [131],
suggesting that zinc is required for neuronal precursor cell
proliferation.When cultured humanNtera-2 (NT2) neuronal
precursor cells were deprived of zinc using the chelator
N,N,N,N-tetrakis(2-pyridylmethyl)ethylenediamine
(TPEN), a significant decrease in cellular proliferation,
as measured by BrdU uptake was observed [131]. When rats
were fed a zinc-deficient (2.7mg zinc/kg) diet for 6 weeks,
a decrease in the number of progenitor cells and immature
neurons was observed in the dentate gyrus. The number of
progenitor cells and immature neurons was restored after a 2-
week reversal to a zinc-adequate (44mg zinc/kg) diet. More-
over, a 1-week treatment with the zinc chelator, clioquinol,
decreased zinc staining in the hippocampus and reduced
the number of progenitor cells. Furthermore, zinc chelation
reduced hypoglycemia-induced progenitor cell proliferation
and neurogenesis [132]. Additionally, ZnT-3 knockout mice,
which lack vesicular zinc [133], had significantly fewer
proliferating progenitor cells and immature neurons after
hypoglycemia [132]. Also, mice fed a zinc-deficient (0.85mg
zinc/kg) diet for 5 weeks displayed reduced vesicular zinc
in CA1 and CA3 regions of the hippocampus, which was
associated with a reduction in proliferating cells labeled
with BrdU and immature neurons labeled with doublecortin
(DCX) immunoreactivity in the dentate gyrus.The processes
of DCX-positive neurons were shortened and flexuously
went through into the granular cell layer in the zinc-deficient
hippocampus, suggesting that zinc deficiency, in addition to
stem cell proliferation, impairs neuronal differentiation [134].
These converging data provide evidence for the important
role of zinc in hippocampal neurogenesis. Zinc was also
found to participate in the regulation of angiogenesis, a
process which accompanies neurogenesis, through effects on
pro- and antiangiogenic factors [135]. In NT2 cells deprived
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of zinc an increase in caspase 3/7-dependent apoptosis was
observed, which was associated with a nuclear translocation
of the tumor suppressor protein p53, a transcription factor
involved in the regulation of cell cycle and apoptosis. The
examination of p53 downstream target genes in zinc-deficient
NT2 cells revealed the induction of a variety of proapoptotic
genes in the initial phase of zinc restriction (6 h after TPEN
treatment), like reprimo gene, which induces G2 cell cycle
arrest, and, in the latter phase (18 h after TPEN treatment),
the induction of proapoptotic genes such as transforming
growth factor-𝛽 (TGF-𝛽) and retinoblastoma-1 (Rb-1), as well
as cellular protection genes such as glutathione peroxidase
(GPx), suggesting that prolonged restriction of zinc induces
mechanisms for cellular protection [131]. The apoptosis
proteins, including Fas, Fas ligand (FasL), apoptosis inducing
factor (AIF), and caspase-3, were significantly activated in
zinc-deficient mouse hippocampus [134]. These data show
that zinc deficiency induces neuronal apoptosis. Studies with
human induced pluripotent stem (iPS) cells differentiated
into motor neurons demonstrated that expression of zinc
homeostasis regulating genes, from the zinc transporters
(ZnTs) family and metallothioneins (MTs), is regulated at
various stages of differentiation, that is, at stages of iPS cells,
embryoid bodies, neural rosettes, neuronal stem cells and
motor neurons. When iPS cells were differentiated using
zinc-deficient medium the number of neuronal stem cells
clusters was reduced. In this study, at this stage no differences
in markers for apoptosis were observed, but increase in the
number of cells undergoing apoptosis was observed at the
stage of embryoid bodies. Importantly, under zinc deficiency
conditions electrophysiological recording revealed a
reduction of glutamate, both AMPAR andNMDAR currents,
and a reduction in the total number of cells responding to
glutamate stimulation [136]. Taken together, the data show
that zinc may have an impact not only on neurogenesis, but
also on synaptogenesis. Zinc is necessary for the structural
integrity of the postsynaptic density (PSD), a specialized
electron dense region of the postsynaptic membrane of
excitatory synapses. The ion was found to influence the
recruitment of ProSAP/Shank proteins, which are observed
at PSD early during synaptogenesis, to PSD during the course
of synaptogenesis and synapsematuration [137]. It was shown
that the overexpression of zinc-sensitive ProSAP1/Shank2
or ProSAP2/Shank3 increases synapse density, whereas
depletion of synaptic zinc along with the knockdown of
zinc-insensitive Shank1 causes the rapid disintegration of
PSD and the loss of several postsynaptic molecules including
NMDARs [137].
NMDARs and AMPARs, which are well known to medi-
ate synaptic plasticity, are among targets for zinc released
from glutamatergic vesicles. NMDAR functions as a het-
eromeric complex composed of four subunits surrounding
a central cation-selective pore. Three major subtypes of
NMDAR subunits have been identified: GluN1, GluN2A-D,
and GluN3A-B [138]. The most widely expressed NMDAR
is composed of two glycine binding GluN1 subunits and two
glutamate-binding GluN2 subunits (GluN2B or GluN2A or a
mixture of the two). Zinc inhibits NMDAR and two different
mechanisms of actionwere described: a voltage-independent,
noncompetitive (allosteric) inhibition, responsible for reduc-
ing channel-opening frequency, and voltage-dependent inhi-
bition, representing an open channel blocking effect of
zinc [36, 139]. The comparison of GluN1/GluN2A and
GluN1/GluN2B receptors showed that the voltage-dependent
inhibition is similar in both types of receptors but the
voltage-independent zinc inhibition is subunit-specific, with
an affinity ranging from lownM forGluN1/GluN2A receptors
to about 1 𝜇M for GluN1/GluN2B receptors and ≥10 𝜇M for
GluN1/GluN2C and GluN1/GluN2D receptors [36]. Recent
study using GluN2A-H128S knockin mice, in which the
high-affinity (nM) zinc inhibition of NMDAR is specifically
eliminated, indicated that under resting conditions zinc levels
are too low for tonic inhibition of GluN2A at hippocampal
mossy fiber synapses, the most zinc enriched synapses in the
brain, which is in contrast to the earlier belief that zinc levels
are high enough to tonically occupy the nM zinc sites. The
study showed that following neuronal activity zinc increases
transiently in the synaptic cleft, where it has a short lifetime
(<2ms at Schaffer collateral-CA1 synapse; <30–40ms at
mossy fiber-CA3 synapses) and reaches concentrations suffi-
cient to occupy the high-affinity (nM), but not the low affinity
(𝜇M), zinc sites on postsynaptic receptors [140]. It should be
noted, however, that the concentration of zinc reached in the
synaptic cleft has long been a matter of debate and has been
estimated to range from sub-𝜇M to over 100 𝜇Maccording to
different groups [40, 140].Moreover, it is plausible that patho-
logical conditions associated with intense neuronal activity
will affect its concentration. Zinc was also found to modulate
another subtype of ionotropic glutamatergic receptors—
AMPARs.These receptors are composed of four types of sub-
units: GluA1, GluA2,GluA3 andGluA4 [141]. GluA2-lacking-
AMPARare permeable forCa2+, which has an important con-
sequences for neural plasticity [142, 143]. At lower concentra-
tions (≈30 𝜇M) zinc potentiates AMPAR-induced currents,
but at higher (mM) concentrations it inhibits them [144].
Stimulation of NMDAR as well as stimulation of GluA2-
lacking-AMPAR results in the Ca2+ influx and induction of
intracellular signaling pathways including: Ca2+-calmodulin-
dependent protein kinase (CaMK), cAMP response ele-
ment binding protein (CREB), BDNF and its receptor,
tropomyosin-related kinase B (TrkB) [145]. BDNF bind-
ing to TrkB induces receptor dimerization and triggers its
intrinsic tyrosine kinase activity, which results in activa-
tion of signaling cascades that lead to enhanced neuronal
survival and differentiation. BDNF signaling via the TrkB
receptor divides into three pathways, all of which con-
verge on CREB, which in turn upregulates gene expression.
These pathways include Ras-microtubule-associated protein
kinase (MAPK)/extracellular signal regulated kinase (ERK)
pathway; phosphatidyl inositol-3 kinase (PI3K)/Akt kinase
pathway; and phospholipase C- (PLC-) 𝛾/CaMK or protein
kinase C (PKC) pathway [145]. Exposure to 𝜇M zinc concen-
trations was found to transactivate TrkB in cultured cortical
neurons [146]. The same group, using brain sections isolated
from ZnT-3 knockout mice, surprisingly found increased
immunoreactivity for activated TrkB in axons but not synap-
tic boutons of hippocampal mossy fibers, which suggested
that vesicular zinc does not activate TrkB in hippocampal
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mossy fiber axons under physiological conditions [147].
However, the latter study does not contradict the previous
one, because under different conditions zinc concentrations
may vary and therefore trigger different effects. Mice fed
with a zinc-deficient diet (0.85mg zinc/kg) for 5 weeks have
decreased protein levels of calmodulin and phosphorylated
CaMKII and CREB in the hippocampus, which was associ-
ated with learning and memory impairments in the Morris
water maze [148]. In turn, exposure to 𝜇M zinc concentra-
tions was found to activateMAPK and ERK1/2 in rat cultured
neurons [149] and an increase in ERK1/2 phosphorylation
was observed after chronic treatment with zinc [150]. Also
activation of GPR39 receptor was found to induce signaling
pathways involved in neural plasticity [32]. GPR39 signals
through G𝛼s, G𝛼q and G𝛼12/13 proteins and displays high
constitutive activity via G𝛼q and G𝛼12/13 but not via G𝛼s
pathway [151]. Downstream kinases of G𝛼s (protein kinase A
(PKA)) and G𝛼q (CaMK, MAPK) activates CREB, whereas
G𝛼12/13 stimulates SRE-mediated transcription [8]. Applica-
tion of𝜇Mzinc concentrations to hippocampal slices induced
phosphorylation of ERK1/2 and CaMKII. Application of the
G𝛼q inhibitor reduced the zinc-dependent phosphorylation
of ERK1/2 and CaMKII, suggesting that activation of G𝛼q
pathway is necessary for the zinc-dependent phosphorylation
of these kinases in CA3 region of the hippocampus [152].
The above-mentioned data, although not exhaustive,
point to the role of zinc in neuro- and synaptogenesis
as well as to the relationship between zinc and signaling
pathways critical for neural plasticity. Importantly, elements
of these signaling pathways were found to participate in the
antidepressant-like activity of zinc and/orwere affected by the
condition of zinc deficiency which concomitantly induced
depressive-like behavior [153].
6.2. Zinc, Monoamine-Based Antidepressants, and Neural
Plasticity: Possible Interactions. As it was shown in the
STAR∗D study the average time required to achieve remis-
sion is 6-7 weeks [4]. A delayed onset of action of
conventional antidepressants and time needed to achieve
response/remission are among the main reasons underly-
ing the need for novel antidepressant treatments. Evidence
indicates that neural adaptations are involved in the mech-
anism of action of conventional antidepressants after chronic
administration [154]. In contrast, a single infusion of sub-
anaesthetic doses of the NMDAR antagonist ketamine exerts
rapid and sustained antidepressant effects in patients with
treatment-resistant depression [155]. Ketamine is NMDAR
channel blocker, which enters the open channel in an activity-
dependent manner and binds with low 𝜇M affinity. After
channel closure, ketamine can become blocked within the
pore, therefore, belongs to “trapping blockers”, whose block
is slow to reverse [156]. As we have already mentioned, zinc,
depending on its concentration, can bind to the subunits of
the NMDAR or block the channel. Allosteric inhibition of
NMDAR by zinc was found to be highly subunit-specific
with an affinity ranging from low nM for GluN1/GluN2A
receptors to about 1 𝜇M for GluN1/GluN2B receptors and
≥10 𝜇M for GluN1/GluN2C and GluN1/GluN2D receptors
[36]. NMDAR open channel block by zinc was described
when the concentrations of the ion were between 20 and
100 𝜇M[156]. It was found that a low dose of ketamine, which
produces antidepressant-like effect in behavioral paradigms
[157], rapidly and transiently activated the mammalian tar-
get of rapamycin (mTOR) signaling pathway, leading to
enhanced and sustained elevation of synaptic proteins expres-
sion (e.g., postsynaptic density protein 95 (PSD95), synapsin
I or GluA1) and an increased number and function of new
synapses in the prefrontal cortex of rats [158]. In contrast,
antidepressants such as imipramine or fluoxetine or elec-
troconvulsive seizures did not significantly influence mTOR
signaling [158]. Recent study demonstrated that a single dose
of zinc (5mg/kg) administered 30 minutes prior to the FST
produced antidepressant-like effect, which lasted up to 3 h
[159]. Unlike ketamine, zinc did not produce a sustained
antidepressant-like effect [159]; however, in contrast to con-
ventional antidepressants (imipramine, fluoxetine) or elec-
troconvulsive seizures [158], it induced a transient (observed
30min and 3 h after the treatment) increase in the protein
levels of phosphorylated mTOR and ribosomal protein S6
kinase (p70S6K). An elevated level of GluA1 and synapsin I
was still observed 24 h after the zinc treatment. In addition,
antidepressant-like effect of zinc in the FST was blocked by
pretreatment with rapamycin, mTOR inhibitor [159], which
suggest that mTOR is involved in the antidepressant-like
action of zinc. Also, blockade of mTOR signaling blocked
ketamine behavioral effects and induction of synaptogenesis
[158]. Although further studies are needed, it is plausible
that the beneficial effects of zinc as an augmentation strategy
in conjunction with imipramine [18] or fluoxetine [7], that
have been observed in clinical trials, result from adding zinc
effects onmTOR to the effects of the above-mentioned drugs,
which lack these action (Figure 1). Moreover, the activation
of glycogen synthase kinase-3 (GSK-3) leads to inhibition of
mTOR pathway [160]. Zinc was found to inhibit GSK-3 [161].
Zinc administered in combination with AR-A014418, GSK-
3𝛽 inhibitor, produced synergistic effects in the FST [162],
suggesting that the antidepressant-like effect of zinc depends
on GSK-3, which further supports the link between zinc and
mTOR with regard to depressive disorders.
Fast-acting behavioral antidepressant-like effect of
ketamine depends also on the rapid synthesis of BDNF.
Enhanced synthesis of BDNF was observed 30min [163]
or 1 h [164] after ketamine administration. In contrast,
conventional antidepressants require weeks to induce an
increase in BDNF protein expression, for example, 2 weeks of
treatment with fluoxetine produced region-specific increase
in BDNF mRNA, whereas BDNF protein level remained
unaltered until 3 weeks of the treatment and reached
significance after 3 weeks in CA1 and CA3 but not in other
subregions of the hippocampus [165]. There were no changes
in the level of BDNF protein in the prefrontal cortex 30min
after zinc treatment [159]. Also, 1 h after zinc administration
Manosso et al. did not observe changes in BDNF protein
levels in either the prefrontal cortex or hippocampus [162].
However, an increase in the level of BDNF protein in
the prefrontal cortex was found 3 h after zinc treatment
[159]. Ranjbar et al. [72] observed in patients with major
depression that zinc supplementation of the therapy with
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Zinc and
monoaminergic systems
Serotonergic system
Abolish antidepressant-like effect of Zn
Abolish antidepressant-like effect of Zn
Adaptive changes in 5-HT receptors
Increased swimming parameter (FST)
Antidepressant-like effect in the FST
Antidepressant-like effect (FST) in the chronic unpredictable stress
More effective than SSRI + placebo in depressed patients
Antidepressant-like effect in the FST and TST
Antidepressant-like effect (FST) in dexamethasone-induced model of depression
More effective than imipramine + placebo in treatment-resistant patients
GPR39 downregulation
Reduced tryptophan level in the hippocampus
Lack of antidepressant-like effect in the FST
Lack of antidepressant-like effect in the FST
Treatment Effect
Noradrenergic system
No changes in the FST
Antidepressant-like effect in the TST
Antidepressant-like effect in the FST and TST
More effective than imipramine + placebo in treatment-resistant patients
No changes in climbing parameter (FST)
Increased immobility time (FST)
Lack of antidepressant-like effect in the FST
(i) Zinc + reboxetine (both in ineffective doses)
(ii) Zinc + desipramine (both in ineffective doses)
(iii) Zinc + imipramine (both in ineffective doses)
(iv) Zinc + imipramine
(v) Zinc
(vi) Zinc deficiency + reboxetine (chronic)
(vii) GPR39 knockout + reboxetine
(viii) Alpha-methyl-p-tyrosine (10 days) GPR39 downregulation in the hippocampus
Dopaminergic system
Antidepressant-like effect in the TST
Increased immobility time in the FST
(i) Zinc + bupropion (both in ineffective doses)
(ii) Zinc deficiency + bupropion (chronic)
(iii) Prenatal exposure to zinc oxide Increased dopamine levels in the hippocampus of mouse offspring
Zinc and
neural plasticity pathways
mTOR
GSK-3𝛽
CREB
BDNF
TrkB
CaMKII
ERK1/2
(i) p-Chlorophenylalanine (pretreatment)
(iii) Zinc (chronic)
(iv) Zinc
(v) Zinc + SSRI (both in ineffective doses)
(vi) Zinc + SSRI (both in ineffective doses)
(vii) Zinc + SSRI
(viii) Zinc + imipramine (both in ineffective doses)
(ix) Zinc + imipramine
(x) Zinc + imipramine
(xi) p-Chlorophenylalanine (10 days)
(xii) GPR39 knockout mice
(xiii) GPR39 knockout + escitalopram (chronic)
(xiv) GPR39 knockout + escitalopram (acute)
(ii) WAY-100635 (5-HT1A antagonist)
Figure 1: The summary of the findings related to interactions between zinc and monoaminergic systems and neural plasticity pathways.
SSRIs (fluoxetine, citalopram) reduced depressive symptoms
more effectively that a respective SSRI and placebo, however,
these effects were not associated with alterations in serum
BDNF level. In contrast, in the study of Solati et al. [20], who
examined zinc treatment as a monotherapy in overweight
or obese subjects with depressive symptoms, a significant
inverse correlationwas observed between serumBDNF levels
and depression severity. Is should be stressed that Solati et
al. [20] found zinc monotherapy to be effective in reducing
depressive symptoms in those subjects. In addition, dietary
zinc deficiency [27] and GPR39-knockout induced decreased
BDNF protein expression in brain regions (hippocampus,
prefrontal cortex) [33], while administration of a GPR39
agonist (TC G-1008), in parallel to antidepressant-like effect,
induced upregulation of BDNF protein in the hippocampus
[34].Thus, mTOR and BDNF pathwaymay be a link between
zinc, depression and neural plasticity.
The proposed sequence of events triggered by ketamine
in depression involves blocking of NMDAR on gamma-
aminobutyric acid- (GABA-) ergic interneurons in the pre-
frontal cortex, which causes disinhibition and increases glu-
tamate release, which primarily excites AMPAR, leading to
activation of BDNF [145]. Ketamine was reported to increase
extracellular glutamate in the prefrontal cortex as measured
by the in vivo microdialysis [166]. Perfusion of the CA1
regions of the hippocampus by zinc was found to decrease
glutamate concentration in the perfusate [167]. Extracellular
glutamate concentration was increased in the hippocampus
of the zinc-deficient rats [168]. Also our study showed an
increase in evoked glutamate release in the prefrontal cortex
of the zinc-deficient rats [169].These studies suggest that zinc,
unlike ketamine, inhibits glutamate release.
Three rapid acting antidepressant agents (ketamine, met-
abotropic glutamate mGlu2/3 receptor antagonist LY341495,
and NMDAR glycine site agent GLYX-13) were found to
rapidly increase the levels of the phosphorylated (activated)
forms of ERK and BDNF release in rat primary cortical
culture neurons [170], showing that ERK signaling is an
important step in antidepressant action. An increase in
ERK1/2 phosphorylationwas observed after chronic (30 days)
treatment with zinc (administered via drinking water that
contained 300mg of zinc chloride/L) and was associated
with antidepressant-like effect in the FST. Moreover, it was
accompanied by an increase in total glutathione levels in the
hippocampus and cerebral cortex [150].
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Of note, relationships between altered zinc homeosta-
sis, increased oxidative/inflammatory status, and NMDAR
function were implicated in depressive disorders [47, 171]. It
was shown that proinflammatory cytokines, such as IL-1𝛽,
and reactive oxygen species can enhance the activity of IDO,
which catabolizes tryptophan into kynurenine, which is fur-
ther catabolized into kynurenic acid and quinolinic acid [46].
Because kynurenic acid is an endogenous antagonist, whereas
quinolinic acid is a strong agonist of the NMDAR, IDO acti-
vation can lead to abnormal function of theNMDAR.Dietary
zinc deficiency-induced depression-like behavior with con-
comitant upregulation of the NMDAR [27] and oxidative as
well as inflammatory parameters (IL-1𝛼, IL-1𝛽) were gener-
ally enhanced in the tissue (serum, prefrontal cortex, and hip-
pocampus) of the zinc deprived rats [169]. Also the study of
GPR39 knockout mice, which display depressive-like behav-
ior, showed immune malfunction: reduced thymus weight,
reduced cell viability of splenocytes and reduced proliferative
response of splenocytes [172]. Further studies are needed
to elucidate changes within the immune system of GPR39
knockout mice as well as effects of antidepressants on zinc
deficiency-induced and GPR39-knockout-induced immune
alterations, that may be linked to neural plasticity events.
It was shown that 5-HT1A knockout mice were insen-
sitive to the effects of chronic fluoxetine administration in
the novelty suppressed feeding test (NSF), which demon-
strates changes in behavior in a response to chronic, but
not acute antidepressant treatment, but were responsive to
imipramine and desipramine. Moreover, when wild-type and
5-HT knockout mice were injected with BrdU, after a 27-day
treatment with fluoxetine, imipramine or vehicle, fluoxetine
caused a doubling of BrdU-labeled cells in the dentate gyrus
of the hippocampus in wild-type mice but had no effect in 5-
HT knockout mice.These results indicate that 5-HT1A recep-
tors are required for fluoxetine-induced neurogenesis [173].
As it was discussed earlier, 5-HT1A receptors are involved
in the antidepressant-like activity of zinc. This observation
may provide another route linking zinc and depression with
regard to neural plasticity.
6.3. Future Perspectives. As it has been discussed, zinc is able
to enhance the effects of conventional, that is, monoamine-
based, antidepressants, not only in preclinical paradigms, but
also in clinical setting. Studies conducted so far point to the
positive effects of zinc supplementation to the therapy with
SSRIs or TCAs. More clinical studies are needed that will
elucidate the possibility of augmentation with zinc a ther-
apy involving antidepressants with different mechanisms of
action (e.g., SNRIs, NRIs, or NDRIs). Given the involvement
of zinc in processes related to neural plasticity, it is plausible
that the beneficial effects of zinc in depressed patients result
from activation of signaling pathways associated with neural
plasticity events.
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[136] S. Pfaender, K. Föhr, A.-K. Lutz et al., “Cellular zinc homeosta-
sis contributes to neuronal differentiation in human induced
pluripotent stem cells,” Neural Plasticity, vol. 2016, Article ID
3760702, 15 pages, 2016.
Neural Plasticity 17
[137] A. M. Grabrucker, “A role for synaptic zinc in ProSAP/Shank
PSD scaffold malformation in autism spectrum disorders,”
Developmental Neurobiology, vol. 74, no. 2, pp. 136–146, 2014.
[138] S. Cull-Candy, S. Brickley, and M. Farrant, “NMDA receptor
subunits: diversity, development and disease,” Current Opinion
in Neurobiology, vol. 11, no. 3, pp. 327–335, 2001.
[139] C. W. Christine and D. W. Choi, “Effect of zinc on NMDA
receptor-mediated channel currents in cortical neurons,” Jour-
nal of Neuroscience, vol. 10, no. 1, pp. 108–116, 1990.
[140] A. M. Vergnano, N. Rebola, L. P. Savtchenko et al., “Zinc
dynamics and action at excitatory synapses,”Neuron, vol. 82, no.
5, pp. 1101–1114, 2014.
[141] G. L. Collingridge, R. W. Olsen, J. Peters, and M. Spedding, “A
nomenclature for ligand-gated ion channels,” Neuropharmacol-
ogy, vol. 56, no. 1, pp. 2–5, 2009.
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